Loading...
XSHG
600488
Market cap671mUSD
Dec 05, Last price  
4.35CNY
1D
-0.46%
1Q
2.35%
Jan 2017
-29.95%
IPO
-24.97%
Name

Tianjin Tianyao Pharmaceutical Co.

Chart & Performance

D1W1MN
XSHG:600488 chart
P/E
35.59
P/S
1.48
EPS
0.12
Div Yield, %
2.00%
Shrs. gr., 5y
0.04%
Rev. gr., 5y
1.98%
Revenues
3.22b
-15.00%
661,330,551585,636,292698,959,130876,889,859887,062,3061,128,131,8441,418,381,6611,642,531,4611,480,538,1541,388,919,0081,404,719,8881,206,600,2281,971,716,5252,427,864,5852,915,700,7743,116,847,8223,748,664,5583,688,929,9333,782,826,6213,215,285,232
Net income
133m
+14.01%
80,803,52644,058,91826,139,16150,223,78765,389,10790,828,63393,198,00398,844,46451,925,70086,583,92278,723,91263,805,667129,808,346153,450,350145,277,87480,575,160108,667,64918,436,815117,052,520133,450,642
CFO
569m
-27.28%
050,721,973162,327,984219,308,547435,133,628116,821,46578,473,75713,227,62384,554,189178,763,589129,501,81263,320,3300189,265,815279,368,978346,884,942316,889,762653,524,527783,008,315569,371,797
Dividend
Jun 14, 20240.087 CNY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Tianjin Tianyao Pharmaceuticals Co., Ltd. engages in the research, manufacture, and export of pharmaceutical APIs in Asia. It primarily provides corticosteroid, cardio cerebrovascular, and analgesic APIs and formulations. The company offers bulk drugs, including dexamethasone, dexamethasone sodium phosphate, dexamethasone acetate, triamcinlone acetonide acetate, prednisone acetate, prednisone, prednisolone, flucinonide, halcinonide, triamcinolone acetonide, clobetasol propionate, betamethasone, methylprednisolone hydrocortisone acetate, methylprednisolone, and triamcinolone. The company is based in Tianjin, China. Tianjin Tianyao Pharmaceuticals Co., Ltd. (SHSE : 600488) operates as a subsidiary of Jinhushen Biomedical Technology Co., Ltd.
URL
http://www.tjpcty.com/
IPO date
Jun 18, 2001
Employees
Domiciled in
CN
Incorporated in
CN

Valuation

Title
CNY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT